KyungDong Pharm home
Prescription Medicines

The Forte-C Tab. 5mg

Product Category
Erectile dysfunction treatment
Active Ingredients
tadalafil
Appearance
Yellow hexagonal film-coated tablets
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength
1 tablet
- Active ingredient: Tadalafil (EP)----5mg
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk).
- Other additives: Sodium lauryl sulfate, microcrystalline cellulose, magnesium stearate, Opadry II yellow (32K620005), sodium starch glycolate, hydroxypropyl cellulose

2. Effectiveness
1. Treatment of erectile dysfunction
For this drug to be effective, it requires sexual stimulation. This drug is not indicated for use by women.

2. Benign prostatic hyperplasia
Treatment of signs and symptoms of benign prostatic hyperplasia

3. Erectile dysfunction and benign prostatic hyperplasia
Treatment of signs and symptoms of erectile dysfunction and benign prostatic hyperplasia in men with erectile dysfunction and benign prostatic hyperplasia

3. Dosage and dosage
Do not crush this medicine. Take one tablet as is.
For oral administration.

1. Erectile Dysfunction
Use in adult men
For patients who are expected to use tadalafil frequently (at least twice a week), the recommended dose is a maximum of 5 mg once daily and is recommended to be taken at the same time of day. The suitability of continuous daily dosing regimens should be reassessed periodically.

2. Once daily use for benign prostatic hyperplasia
The recommended dose of this drug for once-daily administration is 5 mg, taken at approximately the same time every day.

3. Once a day for erectile dysfunction and benign prostatic hyperplasia
The recommended dose of this drug for once-daily administration is 5mg, which should be taken at approximately the same time every day, regardless of the time of sexual activity.

4. Special groups
• Use in elderly men
No dosage adjustments are required in elderly patients.

• Use in men with renal dysfunction
- Erectile dysfunction
No dose adjustment is required in patients with mild to moderate renal impairment. A once-daily dose of tadalafil is not recommended for patients with severe renal impairment [see Precautions for Use 3.2) and 11.2) Pharmacokinetic Properties].
- Benign prostatic hyperplasia
No dose adjustment is required in patients with mild renal impairment. Tadalafil once daily dosage is not recommended for patients with severe renal impairment. [Refer to Precautions for Use 3.3) and 11.2) Pharmacokinetic Properties].

• Use in men with liver dysfunction
Once daily dosing has not been evaluated in patients with hepatic dysfunction. Therefore, when prescribing, doctors must carefully evaluate the individual benefits/risks (see Section 11. <Special Groups>).

• Use in men with diabetes
No dosage adjustment is required in diabetic patients.

• Use in children and adolescents
This drug should not be used in people under 18 years of age.

4. Precautions for use
1. Warning
1) If you wish to administer this drug, you must conduct an appropriate medical evaluation for erectile dysfunction and benign prostatic hyperplasia, determine potential and underlying causes, determine appropriate treatment, and consider warnings, contraindications, and cautious administration.
2) Because of the risks to the heart that accompany sexual activity, before starting treatment for erectile dysfunction, doctors should consider the patient's cardiovascular status. Patients who experience symptoms related to cardiovascular disease after starting sexual activity should refrain from further sexual activity and notify their doctor.
3) With this class of drugs, prolonged erection for more than 4 hours and priapism (painful erection for more than 6 hours) have been rarely reported. If an erection persists for more than 4 hours, the patient should be informed to immediately seek medical assistance. If priapism is not treated immediately, it may result in damage to penile tissue and permanent loss of erectile function.
4) If you take any type of nitrate preparation or NO donor (nitroglycerin, amyl nitrate, isosorbide nitrate) before, during, or after administering this drug, the blood pressure lowering effect may be enhanced and blood pressure may fall excessively. Therefore, the doctor must sufficiently confirm that the patient has not taken nitrate preparations or NO donor before prescribing this drug, and avoid administering nitrate preparations or NO donor during and after administration of this drug. Be careful.
5) Serious adverse cardiovascular events, including myocardial infarction, sudden cardiac arrest, unstable angina pectoris, ventricular arrhythmia, stroke, transient ischemic attacks, chest pain, palpitations, and tachycardia, occurred during clinical studies and/or post-marketing surveillance of this drug. Additionally, hypertension and hypotension (including postural hypotension) were rarely observed in clinical trials. Most of the patients who developed these adverse events had pre-existing cardiovascular risk factors. However, it is not clear whether these adverse events are directly related to cardiovascular risk factors, this drug, sexual behavior, a combination of these factors, or other factors.
6) When tadalafil was administered to dogs at doses of 25 mg/kg/day daily for 6 to 12 months (resulting in an exposure at least 3 times greater than that observed in humans with a single dose of 20 mg [range 3.7 to 18.6]) and higher doses, there was a decrease in seminiferous tubular epithelium leading to a decrease in spermatogenesis in some dogs. There was regression.
To evaluate the potential effects of this drug on spermatogenesis, three clinical studies were conducted in men who took 10 mg of this drug daily for 6 months or 20 mg daily for 6 or 9 months, respectively. In two of these studies, a decrease in sperm count and concentration that did not appear to be clinically relevant was observed in relation to tadalafil treatment. Sperm motility, morphology, follicles
No changes were observed in other measures of follicle stimulating hormone [11. 1) Refer to the pharmacodynamic properties section].
7) Patients with left ventricular outflow obstruction (e.g. aortic stenosis and idiopathic hypertrophic subaortic stenosis) may be sensitive to the action of vasodilators, including PDE5 inhibitors.

2. Do not administer to the following patients
1) Administration of this drug is contraindicated in patients who regularly and/or intermittently take any form of organic nitrate preparation [1. See WARNINGS and 6. INTERACTIONS]. In clinical trials, tadalafil has been shown to increase the hypotensive effect of nitrate. Tadalafil has vasodilating properties, so it temporarily reduces blood pressure slightly [11. 1) Refer to the pharmacodynamic properties section] As a result, the blood pressure lowering effect of nitrate increases. This is believed to be the result of the combined effect of nitrate and tadalafil on the nitric oxide/cGMP pathway.
2) Drugs that treat erectile dysfunction, including this drug, should not be used in men with cardiac disease for whom sexual activity is not recommended. Physicians should consider the potential cardiac risk of sexual activity in patients with preexisting cardiovascular disease.
3) The following patient groups with cardiovascular disease were not included in the clinical trial, so the use of this drug is contraindicated. :
- Patients who have had a myocardial infarction within the last 90 days
- Patients with unstable angina or angina that occurred during sexual intercourse
- Patients who have had heart failure of New York Heart Association Class 2 or higher in the past 6 months
- Patients with uncontrolled arrhythmias, hypotension (<90/50 mmHg), or uncontrolled hypertension (>170/100 mmHg)
- Patients who have had a stroke within the last 6 months
4) Since patients with known genetic degenerative retinal diseases, including retinitis pigmentosa, were not included in the clinical trials, the use of this drug is not recommended.
5) This drug should not be administered to patients with hypersensitivity to tadalafil or any of its components.
6) Because the safety and effectiveness of this drug in combination with other erectile dysfunction treatments have not been studied, concurrent administration with other erectile dysfunction treatments is not recommended.
7) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. (Limited to products containing lactose)
8) Regardless of previous use of PDE5 inhibitors, this drug should not be administered to patients who have lost vision in one eye due to non-arteritic anterior ischemic optic neuropathy (NAION).
9) When coadministering a PDE5 inhibitor, including this drug, and a GC stimulator (Guanylate Cyclase Stimulator) (e.g. Riociguat), the blood pressure lowering effect of the GC stimulator (Guanylate Cyclase Stimulator) may increase, so coadministration of the two drugs is contraindicated.

3. Administer with caution to the following patients:
1) Erectile dysfunction drugs, including this drug, should be administered with caution to patients with anatomically deformed penis (angulation, cavernosal fibrosis, or Peyronies disease) or patients with conditions that may predispose to penile ankylosis (sickle cell anemia, multiple myeloma, or leukemia).
2) Due to the increased tadalafil exposure (AUC), limited clinical data, and lack of clearance by dialysis, once-daily administration of this drug is not recommended for patients with severe renal impairment.
3) In patients with benign prostatic hyperplasia and moderate renal dysfunction, this drug should be administered with caution as clinical data is limited.
4) Since clinical data on the safety of this drug in patients with severe liver dysfunction (Child-Pugh Class C) are limited, doctors must carefully evaluate the individual benefits/risks. In patients with mild to moderate liver dysfunction, the dose of this drug should not exceed 10 mg.
There are no available data on the once-daily dosage of tadalafil for patients with hepatic impairment, so when prescribing tadalafil, doctors must carefully evaluate the individual benefits/risks.
5) Patients receiving alpha-blockers and antihypertensive drugs: Physicians should discuss with patients the possibility of enhancing the blood pressure-enhancing effect of this drug and alpha-blockers and antihypertensive drugs. Caution is required when PDE5 inhibitors are used in combination with alpha-blockers. PDE5 inhibitors, including this drug, and alpha-adrenergic blockers are all vasodilators with a blood pressure lowering effect. When vasodilators are used concomitantly, additive effects on blood pressure are expected. In some patients, the combined use of these two drug classes may significantly lower blood pressure, leading to symptomatic hypotension (e.g. fainting), so the following should be considered: (see interaction 6.2))
● Erectile dysfunction
-Patients should be on stable alpha-blocker therapy before starting PDE5 inhibitors. Patients who exhibit hemodynamic instability during alpha-blocker monotherapy are at increased risk of symptomatic hypotension when combined with PDE5 inhibitors.
- For patients stable on alpha-blocker therapy, PDE5 inhibitors should be initiated at the lowest recommended dose.
- In patients already taking optimal doses of PDE5 inhibitors, alpha-blocker therapy should be initiated at the lowest dose. Stepwise increases in alpha-blocker dosage may be associated with additional reductions in blood pressure when taking PDE5 inhibitors.
- The safety of combined use of PDE5 inhibitors and alpha-blockers may be affected by other variables, including intravascular volume reduction and other antihypertensive drugs.
● Benign prostatic hyperplasia
- The effectiveness of combined administration of alpha-blockers and this drug in the treatment of benign prostatic hyperplasia has not been adequately studied, and due to the potential vasodilatory effect of combined use that causes a decrease in blood pressure, the combined use of this drug and alpha-blockers in the treatment of benign prostatic hyperplasia is not recommended.
- Patients receiving alpha-blocker therapy for benign prostatic hyperplasia should discontinue use of the alpha-blocker before starting the once-daily regimen for the treatment of benign prostatic hyperplasia.
6) Caution should be exercised as an increase in tadalafil exposure (AUC) was observed when co-administering this drug to patients taking strong CYP3A4 inhibitors (ritonavir, saquinavir, ketoconazole, itraconazole, erythromycin) [6. see interaction terms]. When co-administering this drug with a strong CYP3A4 inhibitor, the maximum administered dose of this drug should not exceed 10 mg, and this drug should not be re-administered within 72 hours after administration.
7) It is not known whether this drug is effective in patients who have undergone radical non-nerve-sparing prostatectomy.

4. Adverse reactions
1)Clinical trial experience
Because clinical trials are conducted under various conditions, the incidence of adverse reactions observed in clinical trials of one drug cannot be directly compared to the incidence rate in clinical trials of other drugs, and may not reflect the rates observed in actual clinical trials.
Tadalafil has been administered to more than 9,000 men in clinical trials conducted worldwide. In clinical trials of this drug for once-daily dosing, a total of 1434, 905, and 115 people were treated for at least 6 months, 1 year, and 2 years, respectively. Regarding the as-needed regimen, more than 1,300 and 1,000 people received the drug for at least 6 months and 1 year, respectively.

As needed medication for erectile dysfunction
In eight pivotal placebo-controlled clinical trials conducted over 12 weeks, the average age of patients treated with this drug was 59 years (22-88 years), and the discontinuation rate due to adverse reactions was 3.1% in patients receiving 10 or 20 mg of this drug, compared to 1.4% in the placebo group.
When this drug was administered on an as-needed basis as recommended in placebo-controlled clinical trials, the following adverse reactions were reported (Table 1).
Table 1: Treatment-emergent adverse reactions reported in ≥2% of patients treated with 10 or 20 mg of this drug in eight major placebo-controlled clinical trials of on-demand therapy for erectile dysfunction (including trials in patients with diabetes) and more frequently in those treated with the drug compared to placebo
※Table - Refer to manual

Once daily use for erectile dysfunction
In three placebo-controlled clinical trials conducted for 12 or 24 weeks, the average age of patients treated with this drug was 58 years (21-82 years), and the discontinuation rate due to adverse reactions was 4.1% in patients receiving this drug compared to 2.8% in patients receiving placebo.
The following adverse reactions were reported in clinical trials conducted over a 12-week period (see Table 2)
Table 2: Treatment-emergent adverse reactions reported in more than 2% of patients treated with a once-daily dose (2.5 or 5 mg) in three major placebo-controlled phase 3 clinical trials (including trials in patients with diabetes) of 12 weeks of once-daily treatment with this drug for erectile dysfunction, and more frequently in the drug-treated group compared to placebo
※Table - Refer to manual

The following adverse events were reported over 24 weeks in one placebo-controlled clinical trial (see Table 3)
Table 3: Treatment-related adverse reactions reported in more than 2% of patients receiving once-daily treatment (2.5 or 5 mg) and more frequently reported in the drug-treated group compared to placebo in one placebo-controlled clinical trial in which the drug was administered as a once-daily regimen for 24 weeks for erectile dysfunction
※Table - Refer to manual

Dosage once daily for patients with benign prostatic hyperplasia and concomitant benign prostatic hyperplasia and erectile dysfunction.
In three 12-week, placebo-controlled phase 3 clinical trials (two of which were in patients with benign prostatic hyperplasia and one in patients with both benign prostatic hyperplasia and erectile dysfunction), the median age of patients receiving this drug was 63 years (44-93 years) and the discontinuation rate due to adverse events was 3.6%, compared to 1.6% in placebo-treated patients. Adverse reactions that led to treatment discontinuation and reported by at least two patients receiving this drug included headache, epigastric pain, and myalgia. The following adverse reactions were reported (see Table 4).
Table 4: Treatment-emergent adverse reactions reported in ≥1% of patients treated with 5 mg once daily and at a higher frequency than placebo in 3 placebo-controlled clinical trials during 12 weeks of treatment with this drug once daily in benign prostatic hyperplasia (including 2 trials for benign prostatic hyperplasia and 1 trial for benign prostatic hyperplasia and erectile dysfunction)
※Table - Refer to manual

Additionally, less frequent adverse reactions (<1%) in controlled clinical trials of benign prostatic hyperplasia and erectile dysfunction and benign prostatic hyperplasia include gastroesophageal reflux, epigastric pain, nausea, vomiting, arthralgia, and muscle spasms.

Back pain or muscle pain was reported at the frequencies listed in Tables 1 through 4. In clinical pharmacology trials of this drug, back pain or muscle pain generally occurred 12 to 24 hours after administration and generally resolved within 48 hours. Back pain/myalgia associated with this drug treatment is characterized by diffuse bilateral lower back, gluteal, thigh, or lumbar muscle discomfort and is aggravated by lateral recumbency (lying on one's side). Generally, pain was reported as mild or moderate and resolved without medical treatment, although severe back pain was reported less frequently (<5% of all reports). When medical treatment is indicated, acetaminophen or nonsteroidal anti-inflammatory drugs are generally effective, but in a subset of subjects requiring treatment, mild narcotic (e.g. codeine) analgesics have been used. Overall, approximately 0.5% of all subjects receiving this drug on an as-needed regimen discontinued treatment as a result of back/myalgia. In the 1-year open-label extension trial, back pain and myalgia were reported in 5.5% and 1.3% of patients, respectively. Diagnostic workup, including evaluation for inflammation, muscle damage, or renal damage, revealed no evidence of a medically significant preexisting etiology. The incidence rates for once-daily administration of this drug for erectile dysfunction, benign prostatic hyperplasia, and benign prostatic hyperplasia/erectile dysfunction are shown in Tables 2, 3, and 4. In trials of once-daily use of this drug, adverse reactions of back pain and muscle pain were generally mild or moderate, and the discontinuation rate was <1% for all indications.

In all studies with this drug, changes in color vision were rare (<0.1% of patients). In placebo-controlled clinical trials of as-needed treatment for erectile dysfunction, diarrhea was reported more frequently in patients older than 65 years receiving this drug. (2.5%)

The following lists additional, less frequent adverse reactions (<2%) reported in controlled clinical trials of this drug administered once daily or as needed. The causal relationship between these adverse reactions and this drug is unclear. Excluded from this list are cases that are mild, unlikely to be related to drug use, imprecise, and therefore meaningless.
- Whole body: muscle strength, facial edema, fatigue, pain, peripheral edema
- Cardiovascular system: angina, chest pain, hypotension, myocardial infarction, orthostatic hypotension, palpitations, syncope, tachycardia
- Digestive system: Abnormal liver function test values, dry mouth, dysphagia, esophagitis, gastritis, increased GGTP, loose stools, nausea, epigastric pain, vomiting, gastroesophageal reflux, hemorrhoidal bleeding, rectal bleeding.
- Musculoskeletal system: joint pain, neck pain
- Nervous system: Dizziness, decreased sensation, insomnia, abnormal sensation, drowsiness, dizziness
- Kidney and urinary system: renal impairment
- Respiratory system: Difficulty breathing, epistaxis, pharyngitis
- Skin: itching, rash, sweating
- Ophthalmology: Blurred vision, color vision loss, conjunctivitis (including conjunctival hyperemia), eye pain, increased tear secretion, eyelid edema
- Hearing: sudden decrease or loss of hearing, tinnitus
- Urogenital system: increased erection, spontaneous penile erection

2) Overseas post-marketing experience
The following adverse reactions were identified during the period of use after approval of this drug. Because these reactions are voluntarily reported from a population of unspecified size, it is not always possible to establish a causal link to drug exposure or to reliably estimate their frequency. These adverse events were included due to their severity, frequency of reporting, lack of apparent other causes, or a combination of these factors.

Cardiovascular and Cerebrovascular System - Serious cardiovascular adverse reactions, including myocardial infarction, sudden cardiac death, stroke, chest pain, palpitations, ventricular arrhythmias, and tachycardia, have been reported post-marketing that have been temporally associated with the use of this drug. Most, but not all, of these patients had pre-existing cardiovascular risk factors. Most of these adverse reactions were reported to occur during or shortly after sexual activity, and some were reported to occur immediately after use of this drug without sexual activity. Other adverse reactions have been reported to occur hours to days after use of this drug and sexual activity. It cannot be determined whether these adverse reactions are directly related to this drug, sexual activity, or the patient's existing cardiovascular disease, a combination of these factors, or other factors (see Warning section 1).

Systemic - hypersensitivity reactions, including urticaria, Stevens-Johnson syndrome, and exfoliative dermatitis
Nervous system - migraines, seizures and recurrence of seizures, transient amnesia
Ophthalmology - Non-arteritic anterior ischemic optic neuropathy (NAION), which causes visual field defects (including central serous chorioretinopathy), retinal vein occlusion, retinal artery occlusion, and decreased visual acuity, including permanent vision loss, has been rarely reported post-marketing in association with the use of PDE5 inhibitors, including this drug. Most, but not all, of these patients had pre-existing anatomical or vascular risk factors for the development of NAION, including (but not necessarily limited to): low cup/disc ratio, crowded disc, age over 50, diabetes mellitus, hypertension, coronary artery disease, hyperlipidemia, and smoking. (Refer to section 5. General precautions)
Hearing—Cases of sudden hearing loss or decline have been reported post-marketing in temporal association with the use of PDE5 inhibitors, including this drug. In some cases, medical conditions and other factors that may play a role in auditory adverse reactions have been reported. In many cases, medical follow-up information was limited. It cannot be confirmed whether these reported adverse reactions are directly related to the use of this drug, to the patient's existing risk factors for hearing loss, to a combination of these factors, or to other factors (see section 5. General precautions)
Genitourinary system—priapism (see section 1. Warnings)
Immune System - Angioedema

3) When this drug was administered once a day, electrocardiogram abnormalities and primary sinus bradycardia occurred slightly higher than in the placebo group. Most electrocardiogram abnormalities were unrelated to adverse events.

4) Domestic post-marketing survey results
① Post-marketing surveillance results of Tadalafil 5mg single agent
● As a result of a post-marketing survey conducted on 613 erectile dysfunction patients for 4 years for re-examination in Korea, the adverse event rate was found to be 4.73% (29 people/613 people, 37 cases) regardless of the causal relationship with the drug, and among these, the adverse drug reaction rate for which a causal relationship with the drug could not be ruled out was 3.75% (23 people/613 people, 31 cases).
- Adverse drug reactions were headache 1.14% (7 people/613 people) [7 cases], muscle pain 0.82% (5 people/613 people) [5 cases], flushing 0.65% (4 people/613 people) [4 cases], facial flushing 0.49% (3 people/613 people) [3 cases], itching, nasal congestion, etc. 0.33% (2 people/613 people) [2 cases], and abnormal sensations, visual impairment, palpitations, indigestion, and facial edema were each 0.16% (1 person/613 people) [1 case].
- There were no serious adverse drug reactions.
- The unexpected adverse drug reaction was reported as visual impairment in 0.16% (1 person/613 people) [1 case].
● As a result of a post-marketing survey conducted on 637 patients with benign prostatic hyperplasia over a period of 4 years for re-examination in Korea, the adverse event rate was found to be 2.04% (13 people/637 people, 15 cases) regardless of the causal relationship with the drug, and among these, the adverse drug reaction rate for which a causal relationship with the drug could not be ruled out was 1.26% (8 people/637 people, 8 cases).
- Adverse drug reactions were headache and facial flushing at 0.31% (2 people/637 people) [2 cases], flushing, limb discomfort, facial edema, and decreased semen at 0.16% (1 person/637 people) [1 case].
- There were no serious adverse drug reactions.
- Unexpected adverse drug reactions were reported in 0.16% (1 person/637 people) [1 case] of discomfort in limbs and decreased semen.
② Post-marketing surveillance results of Tadalafil 10mg, 20mg single agent
● As a result of a post-marketing survey conducted on 10,500 patients over 6 years for re-examination in Korea, the adverse event rate was 3.94% (414 people/10,500 people, 517 cases) regardless of the causal relationship with the drug, and among these, the adverse drug reaction rate for which a causal relationship with this drug could not be ruled out was 3.47% (364 people/10,500 people, 517 cases). 461 cases).
- The most common adverse drug reactions were headache and facial flushing at 1.30% (136 people/10,500 people, 136 cases), indigestion at 0.33% (35 people/10,500 people, 35 cases), muscle pain at 0.19% (20 people/10,500 people, 21 cases), and nasal congestion at 0.12%. (13 people/10,500 people, 13 cases), dizziness 0.11% (12 people/10,500 people, 12 cases), colic 0.07% (7 people/10,500 people, 7 cases), priapism 0.06% (6 people/10,500 people, 6 cases), increased blood urea nitrogen 0.06% (6 people/10,500 people, 6 cases), tachycardia 0.05% (5 people/10,500 people, 5 cases), palpitations 0.04% (4 people/10,500 people, 5 cases), bloodshot eyes and increased SGPT each 0.04% (4 people/10,500 people, 4 cases), chest pressure, Vomiting, nausea, increased alkaline phosphatase, fatigue each 0.03% (3 people/10,500 people, 3 cases), neck stiffness, urethral pain, kidney pain, dry mouth, heartburn, gastrointestinal disease, drowsiness, increased white blood cell count, thrombocytopenia, anxiety, sleep disorder, and hemoglobin decrease each 0.02% (2 people/10,500 people, 2 cases), eye pain 0.01% (1 person/10,500 people, 2 cases), chest pain, joint pain, hyperventilation, eye hemorrhage, eyelid swelling, conjunctival hemorrhage, dry eye, abdominal cramps, increased bilirubin, ejaculation disorder, pain in external genital organs, erythema, itching, penile dysfunction, flushing, polydipsia, myocardial infarction, tinnitus, epistaxis, dry nose, creatinine Increased blood pressure, hiccups, asthenia, abdominal discomfort, abdominal pain, allergic reaction, facial edema, fever, increased SGOT, and increased hemoglobin were investigated in the order of 0.01% each (1 person/10,500 people, 1 case).
- The serious adverse drug reaction was facial flushing in 0.02% (2 people/10,500 people, 2 cases).
- The unexpected adverse drug reaction rate was 0.31% (33 people/10,500 people, 37 cases), increased blood urea nitrogen 0.06% (6 people/10,500 people, 6 cases), increased alkaline phosphatase 0.03% (3 people/10,500 people, 3 cases), neck stiffness, increased white blood cell count, anxiety, urethral pain, Kidney pain, decreased hemoglobin, and thrombocytopenia were each 0.02% (2 people/10,500 people, 2 cases), hyperventilation, conjunctival hemorrhage, dry eyes, eye bleeding, polydipsia, hiccups, pain in the external genital tract, ejaculation disorder, fever, penile dysfunction, dry nose, increased creatinine, increased hemoglobin, and erythema. It was investigated at 0.01% (1 person/10,500 people, 1 case).

5) As a result of domestic voluntary side effect reporting, among the side effects that occurred with statistical significance compared to side effects occurring in other medicines for which side effects were reported, unexpected side effects were found as follows. However, the causal relationship with this drug has not been confirmed.
- Ineffective (medicine ineffective)
- Whole body: Chills
- Musculoskeletal system: Skeletal pain

5. General precautions
1) If sudden loss of vision occurs in the patient's eyes (one or both eyes), the doctor should advise the patient to stop using PDE5 inhibitors, including this drug, and take medical attention. These symptoms may be a sign of non-arteritic anterior ischemic optic neuropathy (NAION), a rare disease that can cause vision loss, including visual field defects (including central serous chorioretinopathy) and permanent vision loss, and has been rarely reported in post-marketing surveillance and has been shown to have a tentative correlation with the administration of PDE5 inhibitors. According to published literature, the annual incidence of non-arterial anterior ischemic optic neuropathy is 2.5 to 11.8 cases per 100,000 in men over 50 years of age. In a case-crossover study, the risk of NAION was assessed when PED5 inhibitors were used immediately prior to NAION onset (within 5 half-lives) compared with PDE5 inhibitors used in the preceding period. The study results suggested that the risk of NAION increased approximately two-fold, with a risk estimate of 2.15 (95% CI 1.06, 4.34). Similar trials reported consistent results, with a risk estimate of 2.27 (95% CI 0.99, 5.20). In these trials, other risk factors for NAION, such as the presence of a “crowded” optic disc, may have contributed to the development of NAION. The association of PDE5 inhibitor use with NAION in rare postmarketing reports or observational studies does not support a causal relationship between PDE5 inhibitor use and NAION (see Section 4. Adverse Reactions).
Physicians should consider whether patients with pre-existing risk factors for non-arterial anterior ischemic optic neuropathy may be adversely affected by administration of PDE5 inhibitors. For people who have already experienced non-arterial anterior ischemic optic neuropathy, the risk of recurrence of non-arterial anterior ischemic optic neuropathy is higher. Therefore, caution should be exercised when administering PDE5 inhibitors, including this drug, to these patients, and should be administered only when the expected benefits outweigh the risks (see Section 4. Adverse Reactions).
2) This drug has no experience administering to patients with bleeding abnormalities or active peptic ulcers. Although this drug has not been shown to prolong bleeding time in healthy volunteers, it should be administered cautiously after evaluating the benefits/risks in patients with bleeding abnormalities or active peptic ulcers.
3) Both this drug and alcohol have a mild vasodilating effect, so the blood pressure lowering effect may be enhanced when administered together. Doctors should inform patients that orthostatic signs and symptoms such as increased heart rate, decreased blood pressure, dizziness, and headache may occur when coadministering large amounts of alcohol with this drug.
4) If sudden hearing loss or hearing loss (which may be accompanied by tinnitus and dizziness) occurs, the doctor should advise the patient to stop using PDE5 inhibitors, including this drug, and seek medical attention immediately (see ‘Adverse Reactions’ and ‘Post-Marketing Surveillance’).
5) There is no clinical use experience for Tadalafil 5mg once daily for more than 2 years and 6 months (limited to Tadalafil 5mg single agent).
6) Other urological conditions to consider before starting treatment for benign prostatic hyperplasia: Before starting treatment with this drug for benign prostatic hyperplasia, other urological conditions that may cause similar symptoms should be considered. Additionally, prostate cancer and benign prostatic hyperplasia can occur together.

6. Interaction
As seen below, many interaction studies have been conducted with tadalafil 10 mg and/or 20 mg. Regarding interaction studies using only the 10 mg dose of tadalafil, the possibility of clinically significant interactions occurring at higher doses cannot be completely excluded.
1) Actions of other drugs on tadalafil
- Tadalafil is mainly metabolized by CYP3A4. Ketoconazole (200 mg per day), a selective inhibitor of CYP3A4, doubled the AUC of tadalafil (10 mg) and increased Cmax by 15% compared to the AUC and Cmax values ​​when tadalafil was administered alone. Ketoconazole (400 mg per day) increased the AUC of tadalafil (20mg) by 4 times and Cmax by 22%.
- Ritonavir (administered 200 mg twice daily), a protease inhibitor that inhibits CYP3A4, CYP2C9, CYP2C19, and CYP2D6, doubled the AUC of tadalafil (20 mg) without changing Cmax.
- Although specific interactions have not been studied, other protease inhibitors, such as saquinavir, and other CYP3A4 inhibitors, such as erythromycin, clarithromycin, itraconazole, and grapefruit juice, are expected to increase plasma concentrations of tadalafil and should be coadministered with caution. As a result, the frequency of adverse reactions listed in Section 4 may increase.
- Rifampicin, a CYP3A4 inducer, reduced the AUC of tadalafil by 88% compared to the AUC value when tadalafil was administered alone (10 mg dose). This may reduce the efficacy of tadalafil, but the extent of this reduction is unknown. It can be expected that co-administration with other CYP3A4 inducers such as phenobarbital, phenytoin, and carbamazepine may also decrease the plasma concentration of tadalafil.
- The role of transporters (e.g. p-glycoprotein) in the distribution of tadalafil is unknown. Therefore, there is a possibility of drug interaction due to inhibition of transporters.
- When co-administered with this drug and antacids (magnesium hydroxide/aluminum hydroxide), the absorption rate of this drug was clearly decreased without changing the exposure (AUC) of this drug.

2) Action of tadalafil on other drugs
- In clinical trials, tadalafil (5mg, 10mg and 20mg) has been shown to increase the blood pressure lowering effect of nitrates. Therefore, administration of this drug is contraindicated in patients who regularly and/or intermittently take any form of organic nitrate preparation [1. [See Warning and 2. Do not administer to the following patients]. According to clinical trial results, when 150 patients were administered 20 mg of tadalafil daily for 7 days and 0.4 mg nitroglycerin sublingual tablets at various times, this interaction lasted for more than 24 hours and no longer occurred 48 hours after the last dose of tadalafil. Therefore, if a patient who has administered this drug (tadalafil 2.5mg-20mg) is in a life-threatening situation and administration of nitrates is medically necessary, administration of nitrates can be considered only after at least 48 hours have passed since the last administration of this drug. In such situations, nitrate administration should be accompanied by careful physician supervision with appropriate haemodynamic monitoring.
- Tadalafil is not expected to significantly inhibit or induce clinically significant clearance of drugs metabolized by CYP450 isoforms. Clinical trials have shown that tadalafil does not inhibit or induce CYP450 isoforms, including CYP3A4, CYP1A2, CYP2D6, CYP2E1, CYP2C9, and CYP2C19.
- Tadalafil (10 mg, 20 mg) did not show clinically significant effects on exposure (AUC) to S-warfarin or R-warfarin (CYP2C9 substrate), and tadalafil did not affect changes in prothrombin time induced by warfarin.
- Tadalafil (10mg, 20mg) did not increase bleeding time caused by acetylsalicylic acid.
- In a clinical pharmacology study, the possibility of tadalafil increasing the blood pressure lowering effect of antihypertensive drugs was investigated. Calcium channel blockers (amlodipine), angiotensin converting enzyme (ACE) inhibitors (enalapril), beta-adrenergic receptor blockers (metoprolol), thiazide diuretics (bendrofluazide), angiotensin II receptor blockers (in various forms and doses, alone or as thiazides, calcium channel blockers, beta-blockers, and/or The major classes of antihypertensive agents were studied, including those used in combination with alpha-blockers. Tadalafil (10 mg, excluding studies with angiotensin II receptor blocker and amlodipine, which used the 20 mg dose) did not have clinically significant interactions with any drugs in this class.
- In another clinical pharmacology study, 20 mg of tadalafil was administered in combination with up to four types of antihypertensive drugs. In patients receiving various antihypertensive treatments, changes in ambulatory blood pressure were found to be related to the degree of blood pressure control. In this regard, in patients with poor blood pressure control, the reduction was greater, although this reduction was not associated with hypotensive symptoms in most patients. In patients with well-controlled blood pressure, the decrease in blood pressure was small and similar to that seen in healthy people.
- In patients taking concomitant antihypertensive medications, tadalafil 20 mg may cause a decrease in blood pressure (except for alpha-blockers, see below), which is generally considered to be insignificant and not clinically significant. As a result of analysis of phase 3 clinical trial data, there was no difference in adverse reactions between the patient group who took this drug in combination with antihypertensive drugs and the patient group who took this drug without antihypertensive drugs. However, appropriate clinical advice should be given to patients regarding the possibility of decreased blood pressure when combined with antihypertensive drugs.
- In patients who took the alpha(1)-adrenergic receptor blocker doxazosin (4 mg or 8 mg per day) in combination with tadalafil (5 mg once per day or 20 mg single dose), the blood pressure lowering effect of doxazosin increased significantly. This effect can still be seen up to 12 hours after administration and symptoms including fainting may occur. Therefore, combined use of tadalafil and doxazosin is not recommended.
- In an interaction study involving a limited number of healthy volunteers, no clinically significant changes in blood pressure were reported when tadalafil (10 mg, 20 mg) was coadministered with alfuzosin or tamsulosin, a selective alpha(1A)-adrenergic receptor blocker. However, caution should be exercised when using tadalafil in patients being treated with alpha-blockers and especially in the elderly. Treatment should be started with the lowest dose and adjusted gradually.
- Alcohol concentration (mean maximum blood concentration 0.08%) was not affected by co-administration of tadalafil (10 mg or 20 mg). Additionally, no change in tadalafil concentration occurred 3 hours after co-administration of alcohol.
Alcohol was administered in a way that maximized its absorption effect (fasting overnight and withholding food for 2 hours after alcohol administration). When tadalafil (20 mg) was coadministered with alcohol, tadalafil did not increase the mean decrease in blood pressure induced by high doses of alcohol (0.7 g/kg, or approximately 180 ml of 40% alcohol [vodka] in an 80 kg man), but positional dizziness and orthostatic hypotension were observed in some patients. When tadalafil was administered with a low dose of alcohol (0.6g/kg), hypotension was not observed and dizziness occurred at a frequency similar to when administered with alcohol alone. The effect of alcohol on cognitive function was not increased by tadalafil (10 mg).
- Tadalafil has been shown to increase the oral bioavailability of ethinylestradiol. A similar increase may be expected with oral administration of terbutaline, although its clinical significance is uncertain.
- In a clinical pharmacology study, there was no pharmacokinetic interaction when 10 mg of tadalafil was administered together with theophylline (a non-selective phosphodiesterase inhibitor). The only pharmacodynamic effect was a slight increase in heart rate (3.5 bpm). Although this effect was not significant and had no clinical significance in this study, this effect should be taken into consideration when administering these drugs together.
- Specific interaction studies with antidiabetic drugs have not been conducted.

7. Administration to pregnant women, lactating women and children
1) This drug cannot be used on women, newborns, and children.
2) In animal experiments on rats, tadalafil and/or its metabolites passed through the placenta and were secreted into milk at a concentration about 2.4 times higher than the concentration detected in the blood. The use of tadalafil in pregnant women has not been studied.
3) There was no evidence of teratogenicity, embryotoxicity, or fetotoxicity in rats or mice administered up to 1,000 mg/kg/day.

8. Effects on ability to drive and use machines
This drug is expected to have no or negligible effects on the ability to drive or use machines. No specific studies have been conducted to evaluate these potential effects. Clinical trials have shown similar incidences of dizziness in the placebo and tadalafil groups, but patients should be aware of how they react to this drug before driving or operating machinery.

9. Treatment in case of overdose
1) A single dose of up to 500 mg has been administered to healthy subjects, and a daily dose of up to 100 mg has been administered multiple times to patients. Adverse reactions were similar to those found at lower doses.
2) In case of overdose, standard supportive measures are implemented if necessary. Hemodialysis has little effect on tadalafil excretion.

10. Precautions for storage and handling
1) Keep out of sight and reach of children.
2) Keep the product in its original packaging as changing it to another container may cause an accident or is undesirable in terms of maintaining quality.

11. Others
1) Pharmacodynamic properties
Tadalafil is a selective, reversible inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). When sexual stimulation causes local release of nitric oxide, inhibition of PDE5 by tadalafil increases cGMP levels in the corpus cavernosum. This causes smooth muscle relaxation and blood flow to the penile tissue, resulting in an erection. Tadalafil is not effective in the absence of sexual stimulation.

The inhibitory effect of PDE5 on cGMP concentration in the corpus cavernosum and pulmonary artery was also observed in the smooth muscle of the prostate, bladder, and blood vessels supplying them. The mechanism of action that alleviates the symptoms of benign prostatic hyperplasia has not been revealed.

In vitro test results show that tadalafil is a selective inhibitor of PDE5. PDE5 is an enzyme found in cavernosal smooth muscle, prostate and bladder, vascular and visceral smooth muscle, skeletal muscle, platelets, kidney, lung and cerebellum. The effect of tadalafil is greater against PDE5 than other phosphodiesterases. Tadalafil has more than 10,000 times greater efficacy against PDE5 than against PDE1, PDE2, and PDE4, enzymes found in the heart, brain, blood vessels, liver, and other organs. This selectivity for PDE5 over PDE3 is important because PDE3 is an enzyme involved in cardiac contractility. Additionally, tadalafil is about 700 times more effective against PDE5 than PDE6, an enzyme found in the retina and responsible for phototransduction. Tadalafil also has greater efficacy against PDE5 than PDE7-PDE10, exceeding 10,000 times.

To clarify the duration of response to this drug (dosage as needed), three clinical trials were conducted on 1,054 patients in an at-home setting. This drug statistically significantly improved erectile dysfunction, and compared to placebo, it was proven that not only was an erection for successful intercourse maintained 16 minutes after administration, but patients were able to have successful sexual intercourse up to 36 hours after administration.

When administered to healthy subjects, there were no significant differences compared to placebo in supine systolic and diastolic blood pressure (mean maximum reductions of 1.6/0.8 mmHg, respectively), standing systolic and diastolic blood pressures (mean maximum reductions of 0.2/4.6 mmHg, respectively), and no significant differences in heart rate.

In a study to evaluate the action of tadalafil on vision, no impairment of color discrimination (blue/green) was detected using the Farnsworth-Munsell 100-hue test. These results are consistent with the lower affinity of tadalafil for PDE6 compared to PDE5. Across all clinical trials, reports of changes in color vision were rare (<0.1%).

To evaluate the potential effects of this drug on spermatogenesis, three clinical studies were conducted in men who took 10 mg of this drug daily for 6 months or 20 mg daily for 6 or 9 months, respectively. Two of these studies observed reductions in sperm count and concentration associated with tadalafil treatment, which do not seem to have clinical relevance. No changes were observed in other measures of sperm motility, morphology, or follicle stimulating hormone [see Warning section 1].

Tadalafil 2.5, 5, and 10 mg once daily was evaluated for the first time in three clinical trials involving 853 patients (multiple races, age range: 21 to 82 years) with erectile dysfunction of varying severity (mild, moderate, and severe) and etiology. Among these, as a result of evaluating the primary efficacy in two clinical trials targeting the general population, it was reported that the success rate of intercourse attempts was 57%, 67% for 5 mg of this drug, and 50% for 2.5 mg, compared to 31% and 37% for placebo. In addition, in the remaining clinical trial targeting patients with erectile dysfunction accompanied by diabetes, it was reported that 5 mg of this drug was used in 41% of patients and 2.5 mg was used in 46% of patients compared to 28% of placebo. Most patients in these three clinical trials had previously responded to as-needed PDE5 inhibitors.

Afterwards, 217 patients who had no experience taking PDE5 inhibitors were randomly assigned to a tadalafil 5 mg once daily group and a placebo group. As a result, the average sexual intercourse success rate per subject was 69% and 52% in the tadalafil and placebo groups, respectively.

In a 12-week trial of 186 patients with erectile dysfunction due to spinal cord injury (142 receiving tadalafil and 44 receiving placebo), in patients treated with 10 mg or 20 mg of tadalafil (flexible dose, on demand), 48% of patients treated with the drug had significantly improved erectile function on average for each individual, compared to 17% with placebo.

2) Pharmacokinetic properties
① Absorption
Tadalafil is rapidly absorbed after oral administration, and the observed average maximum plasma concentration (Cmax) was reached at a median of 2 hours after administration. The absolute bioavailability of tadalafil after oral administration has not been determined.
The absorption rate and extent of tadalafil are not affected by meals, so this medicine can be taken with or without meals. Dosage time (morning vs. evening) had no clinically relevant effect on absorption rate or extent.
② Distribution
The average distribution volume is about 63 L, which indicates that tadalafil is distributed to tissues. At therapeutic concentrations, 94% of tadalafil in plasma is bound to proteins. Protein binding is not affected by renal dysfunction.
Less than 0.0005% of the administered dose was found in the semen of healthy subjects.
③ Biotransformation
Tadalafil is mainly metabolized by cytochrome P450 (CYP) 3A4 isoform. The main circulating metabolite is methylcatechol glucuronide. This metabolite is at least 13,000 times less potent than tadalafil against PDE5. Therefore, it is not expected to be clinically active at the observed metabolite concentrations.
④ Excretion
The average oral clearance of tadalafil in healthy subjects is 2.5 L/hour and the average half-life is 17.5 hours. Tadalafil is predominantly excreted as an inactivated metabolite, mainly in feces (approximately 61% of the administered dose) and to a lesser extent in urine (approximately 36% of the administered dose).
⑤ Linearity/non-linearity
In healthy subjects, the pharmacokinetics of tadalafil are linear with respect to time and dose.
In the dose range of 2.5-20 mg, exposure (AUC) increases proportionally with dose. When administered once a day, steady-state plasma concentrations are reached within 5 days.
Pharmacokinetics determined using a population approach in patients with erectile dysfunction are similar to pharmacokinetics in subjects without erectile dysfunction.

<Special groups>
① Elderly people
Healthy older subjects (65 years or older) had a lower oral clearance of tadalafil compared to healthy subjects aged 19 to 45 years, resulting in a 25% higher exposure (AUC). This age effect is not clinically significant and does not justify dose adjustment.
② Renal dysfunction
In a clinical pharmacology study using a single dose (5-20 mg) of tadalafil in subjects with mild (creatinine clearance 51-80 mL/min) or moderate (creatinine clearance 31-50 mL/min) renal impairment and end-stage renal failure on dialysis, the exposure (AUC) of tadalafil was approximately doubled. In hemodialysis patients, Cmax was observed to be 41% higher than that in healthy subjects. Hemodialysis has little effect on tadalafil excretion.
③ Liver dysfunction
When administered at a 10 mg dose, the exposure (AUC) of tadalafil in subjects with mild or moderate hepatic impairment (Child-Pugh Class A and B) was comparable to that in healthy subjects. Clinical data on the safety of this drug in patients with severe liver dysfunction (Child-Pugh Class C) are limited, so when prescribing it, doctors must carefully evaluate the individual benefits/risks.
There are no data available regarding the administration of tadalafil doses higher than 10 mg in patients with hepatic impairment.
There are no available data on the once-daily dosage of tadalafil for patients with hepatic impairment, so when prescribing tadalafil, doctors must carefully evaluate the individual benefits/risks.
④ Diabetic patients
The exposure (AUC) of tadalafil in diabetic patients was approximately 19% lower than the AUC value in healthy subjects. These differences in exposure do not justify dose adjustments.

3) Preclinical safety data
Preclinical data based on conventional studies on safety pharmacology, genotoxicity, carcinogenic potential, and reproductive toxicity do not indicate a particular risk to humans.
There was no evidence of teratogenicity, embryotoxicity, or fetotoxicity in rats or mice administered up to 1,000 mg/kg/day. In a rat pre- and postnatal development study, the no observed effect dose was 30 mg/kg/day. The AUC for calculated free drug at this dose in pregnant rats was approximately 18 times the human AUC at a 20 mg dose.
There was no impairment of fertility in male and female rats. When tadalafil was administered to dogs at doses of 25 mg/kg/day and higher daily for 6 to 12 months, there was degeneration of the seminiferous tubular epithelium leading to decreased spermatogenesis in some dogs [1. See warnings and section 11.1) Pharmacodynamic properties].

4) When initially used in combination with finasteride to treat symptoms of benign prostatic hyperplasia, the increased therapeutic benefit of combined administration compared to finasteride alone began to decrease 4 weeks after starting treatment. The benefit of combined use for longer than 26 weeks is unknown.

5. How to save
Airtight container, stored at room temperature (1∼30℃)

6. Packaging unit
30 tablets (10 tablets/PTP

7. Validity period
36 months from date of manufacture

Product Updates

Total 5items

No.Product NameDetailsDate of ChangeDownload
5The Forte-C Tab. 5mgPrecautions for use2025.01.15PDF0051_201502217_The Forte C Tablet 5mg_Precautions for Use (Change).pdf
4The Forte-C Tab. 5mgPrecautions for use2021.02.05HWPPermission change order (draft) and change comparison table_Tadalafil_single drug (oral drug).hwp
3The Forte C tablet 5mgThe Forte C tablet 5mg (Precautions for use...2017.08.09HWP(Tablet 5mg) 1. ~ 56. Tadalafil single agent.hwp
2The Forte C tablet 5mgThe Forte C tablet 5mg (Precautions for use...2017.07.03HWPPrecautions for use of The Forte C Tablet 5mg.hwp
1The Forte C tablet 5mgThe Forte C tablet 5mg (efficacy, dosage, usage...2016.08.16HWPTadalafil single drug 5 mg, oral unified adjustment plan.hwp